Recurrent loss of function mutations of ZMYM3 have been identified in several cancers including chronic lymphocytic leukemia, medulloblastoma, Ewing sarcoma and pediatric cancers (83–88). Here, ZMYM3 is linked to B-cell chronic lymphocytic leukemia.